Table 1.
Overall Antibiotic Use and Duration of Therapy over Study Period*
| Antibiotic Use | No. of Orders | Median DOT/1000 Patient-Days (and IQR) [all data values corrected] |
|---|---|---|
| Route [heading corrected] | ||
| Total antibiotics, any route† | 835 | 38.97 (29.06–43.87) |
| PO | 594 | 27.63 (21.73–33.78) |
| IV | 208 | 6.93 (6.09–9.62) |
|
| ||
| Total use, by class, subclass, or individual drug | ||
| Aminoglycosides | 10 | 0.00 (0.00–0.26) |
| Carbapenems | 2 | 0.00 (0.00–0.07) |
| Cephalosporins | 251 | 9.82 (7.14–13.85) |
| First-generation | 81 | 3.41 (2.47–5.29) |
| Second-generation | 54 | 2.04 (1.40–3.27) |
| Third-generation | 116 | 4.41 (3.17–5.05) |
| Clindamycin | 15 | 0.30 (0.03–1.79) |
| Fluoroquinolones | 235 | 9.62 (7.84–13.18) |
| Ciprofloxacin | 127 | 4.89 (3.50–8.21) |
| Levofloxacin | 105 | 3.72 (3.38–5.02) |
| Moxifloxacin | 3 | 0.00 (0.00–0.14) |
| Macrolides | 56 | 0.90 (0.38–1.40) |
| Metronidazole | 43 | 1.92 (1.05–2.83) |
| Nitrofurantoin | 39 | 1.90 (1.50–2.26) |
| Penicillins | 103 | 4.42 (3.62–6.58) |
| Amoxicillin | 49 | 1.75 (1.24–2.39) |
| Amoxicillin–clavulanate | 7 | 0.11 (0.00–1.33) |
| Ampicillin | 9 | 0.04 (0.00–0.35) |
| Cloxacillin | 20 | 0.77 (0.22–2.28) |
| Penicillin | 1 | 0.00 (0.00–0.00) |
| Piperacillin–tazobactam | 17 | 0.37 (0.12–0.88) |
| Rifampin | 4 | 0.00 (0.00–0.14) |
| Sulfamethoxazole–trimethoprim | 41 | 2.79 (1.69–3.30) |
| Tetracyclines | 16 | 0.85 (0.00–1.93) |
| Vancomycin IV | 4 | 0.00 (0.00–0.17) |
| Vancomycin PO | 16 | 0.37 (0.02–0.67) |
DOT = days of therapy, IQR = interquartile range, IV = intravenous, PO = by mouth.
*
Study period was April 1, 2011, to March 31, 2012 (12 months), and the total number of patient-days was 162 080, with an average of 13 507 patient days per month used for monthly (12 data points, 1 data point per month) DOT/1000 patient-days statistics [addition to footnote shown in bold].
†
Routes of administration: IV, oral, gastric tube, intraperitoneal, and topical.